ATLANTA, GA – – (Globe Newswire – January 16, 2026) – – A shareholder class action lawsuit has been filed against Vistagen Therapeutics, Inc. (“Vistagen” or the “Company”) (NASDAQ: VTGN). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts regarding the risks of failure associated with Vistagen’s Phase 3 PALISADE-3 trial study of fasedienol.

If you purchased Vistagen shares between April 1, 2024 and December 16, 2025, and experienced a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/vistagen-therapeutics/ for more information.

The deadline to ask the court to be appointed lead plaintiff in the case is March 16, 2026.